New cancer Drug's interaction with other meds under scrutiny in early trial

NCT ID NCT07372625

Recruiting now Knowledge-focused Sponsor: PMV Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal is to see if rezatapopt changes the levels of these other drugs in the blood. Only 14 participants will be enrolled, and the study is primarily about safety and drug interactions, not about curing the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rezatapopt
What this could lead to: If successful, this study could help doctors understand how rezatapopt interacts with common medications, guiding safer use in future treatments.
What could go wrong: This is a very early, small phase 1 trial with only 14 participants. It focuses on drug interactions, not on treating the cancer itself, so it may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS TP53 Y220C MUTATION

Contacts and locations

Show contact details

Locations

Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States

Contact Email: •••••@•••••
HealthOne Denver
RECRUITING

Denver, Colorado, 80237, United States

Contact Email: •••••@•••••
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States

Contact Email: •••••@•••••
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States

Contact Email: •••••@•••••
SCRI at Mary Crowley
RECRUITING

Dallas, Texas, 75230, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.